Jumpcan subsidiary allocates 220 million yuan to cash management

Hubei Jumpcan Pharmaceutical announced that its wholly-owned subsidiary, Hubei Jumpcan Pharmaceutical Group Co., Ltd., has opened dedicated settlement accounts for cash management of raised funds with Suzhou Bank and China Galaxy Securities. The subsidiary has allocated 220 million yuan to cash management, including 170 million yuan for Suzhou Bank's 2025 Series 896 customized structured deposit (182 days) and 50 million yuan for China Galaxy Securities' "Galaxy Gold" Income Certificate 5379 Series (181 days).

This initiative follows approvals from the company's Tenth Board of Directors and the 2024 Annual General Meeting, allowing the use of up to 580 million yuan of idle raised funds for cash management. These investments are in high-security, high-liquidity, principal-protected products with maturities under 12 months. The decision aims to enhance the efficiency of capital utilization without impacting ongoing investment projects.

As of the announcement date, 240 million yuan in previously invested funds have been redeemed, yielding 3.1285 million yuan, representing an annualized return of 2.60%. The company emphasizes that these low-risk products are subject to market fluctuations but align with its internal risk control and cash management policies.